CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban.
D A SychevO A BaturinaK B MirzaevEric RytkinDmitriy V IvashchenkoDenis AndreevKristina Anatolyevna AkmalovaE A GrishinaPavel O BochkovRoman ShevchenkoPublished in: Pharmacogenomics and personalized medicine (2020)
In situations of double or triple antithrombotic rivaroxaban and clopidogrel therapy among patients with atrial fibrillation and acute coronary syndrome, the genetic factors associated with bleeding complications risk (CYP2C19*17) may prove to be clinically relevant.